These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28855073)

  • 21. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
    Tutone M; Bjerklund Johansen TE; Cai T; Mushtaq S; Livermore DM
    Int J Antimicrob Agents; 2022 May; 59(5):106574. PubMed ID: 35307561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility testing of urinary isolates of Escherichia coli to mecillinam using NCCLS methodology.
    Skov R; Frimodt-Moller N; Menday P; Espersen F
    Int J Antimicrob Agents; 2005 Mar; 25(3):198-204. PubMed ID: 15737512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
    Syre H; Hetland MAK; Bernhoff E; Bollestad M; Grude N; Simonsen GS; Löhr IH
    APMIS; 2020 Mar; 128(3):232-241. PubMed ID: 31755584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli indicates low propensity for clonal spread.
    Poulsen HO; Johansson A; Granholm S; Kahlmeter G; Sundqvist M
    J Antimicrob Chemother; 2013 Sep; 68(9):1974-7. PubMed ID: 23640126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole.
    Kerrn MB; Frimodt-Møller N; Espersen F
    Clin Microbiol Infect; 2004 Jan; 10(1):54-61. PubMed ID: 14706087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients].
    Marković T; Jeinić L; Smitran A; Petković M
    Srp Arh Celok Lek; 2013; 141(11-12):775-9. PubMed ID: 24502096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of subinhibitory concentrations of mecillinam on the serum susceptibility of Escherichia coli strains.
    Taylor PW; Gaunt H; Unger FM
    Antimicrob Agents Chemother; 1981 May; 19(5):786-8. PubMed ID: 6271047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary tract infections in Norway: bacterial etiology and susceptibility. A retrospective study of clinical isolates.
    Grude N; Tveten Y; Kristiansen BE
    Clin Microbiol Infect; 2001 Oct; 7(10):543-7. PubMed ID: 11683794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption.
    Frimodt-Møller N; Simonsen GS; Larsen AR; Kahlmeter G
    J Antimicrob Chemother; 2022 Dec; 78(1):289-295. PubMed ID: 36441168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women.
    Monsen TJ; Holm SE; Ferry BM; Ferry SA
    APMIS; 2014 Apr; 122(4):317-23. PubMed ID: 24738161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidrug resistance and extended-spectrum β-lactamases genes among Escherichia coli from patients with urinary tract infections in Northwestern Libya.
    Abujnah AA; Zorgani A; Sabri MA; El-Mohammady H; Khalek RA; Ghenghesh KS
    Libyan J Med; 2015; 10(1):26412. PubMed ID: 25651907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mecillinam resistance in Escherichia coli: dissociation of growth inhibition and morphologic change.
    Barbour AG; Mayer LW; Spratt BG
    J Infect Dis; 1981 Jan; 143(1):114-21. PubMed ID: 6260864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of antimicrobial resistant Escherichia coli from patients with suspected urinary tract infection in primary care, Denmark.
    Córdoba G; Holm A; Hansen F; Hammerum AM; Bjerrum L
    BMC Infect Dis; 2017 Oct; 17(1):670. PubMed ID: 29017466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia.
    Ny S; Edquist P; Dumpis U; Gröndahl-Yli-Hannuksela K; Hermes J; Kling AM; Klingeberg A; Kozlov R; Källman O; Lis DO; Pomorska-Wesołowska M; Saule M; Wisell KT; Vuopio J; Palagin I;
    J Glob Antimicrob Resist; 2019 Jun; 17():25-34. PubMed ID: 30447337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracellular uropathogenic Escherichia coli are undetectable in urinary bladders after oral mecillinam treatment: An experimental study in a pig model of cystitis.
    Stærk K; Grønnemose RB; Palarasah Y; Lund L; Andersen TE
    Microb Pathog; 2022 Dec; 173(Pt A):105817. PubMed ID: 36244593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mecillinam in urinary tract infections and in septicaemia.
    Frimodt-Møller N; Ravn TJ
    Infection; 1979; 7(1):35-7. PubMed ID: 217836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the UK.
    Cottell JL; Webber MA
    J Med Microbiol; 2019 Feb; 68(2):161-168. PubMed ID: 30543320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.